Quanterix corp (QTRX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating activities
Net loss

-43,001

-40,796

-39,172

-36,959

-33,739

-31,536

-29,584

-28,541

-27,830

-27,019

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense

3,646

3,009

2,520

1,696

1,489

1,352

1,165

876

650

482

0

0

0

Inventory step-up amortization

0

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

7,213

6,388

6,204

6,243

5,532

4,884

4,130

2,886

2,546

2,168

0

0

0

Non-cash interest expense

87

89

105

117

141

170

188

208

216

238

0

0

0

Loss on disposal of fixed assets

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of preferred stock warrants

-

-

-

-

-

-

-

-

-

90

0

0

0

Changes in operating assets and liabilities:
Accounts receivable

4,074

3,365

6,617

5,502

2,596

983

235

250

798

1,682

0

0

0

Prepaid expenses and other assets

348

-289

1,179

845

763

1,828

668

734

943

273

0

0

0

Inventory

3,047

3,447

4,570

3,421

2,468

1,603

1,984

2,420

2,811

2,043

0

0

0

Other non-current assets

-8

21

0

0

0

-

-

-

-

-

-

-

-

Accounts payable

797

621

331

344

674

1,318

458

937

740

1,003

0

0

0

Accrued compensation and benefits, other accrued expenses and other current liabilities

-561

822

1,729

2,727

2,678

1,101

636

-87

-280

2,035

0

0

0

Contract acquisition costs

251

336

0

0

0

-

-

-

-

-

-

-

-

Operating lease liabilities

0

-

-

-

-

-

-

-

-

-

-

-

-

Other non-current liabilities

3,586

9,845

0

0

0

-

-

-

-

-

-

-

-

Deferred revenue

-82

-708

0

-1,628

-1,273

-1,849

-1,280

316

313

2,895

0

0

0

Net cash used in operating activities

-34,014

-26,187

-29,760

-27,571

-24,012

-28,721

-25,015

-25,857

-28,175

-22,106

0

0

0

Investing activities
Purchases of property and equipment

5,356

10,847

10,424

10,658

6,987

1,518

1,736

1,159

1,413

1,132

0

0

0

Acquisition of UmanDiagnostics AB, net of cash acquired

-

-

-

-

-

3,801

0

0

0

-

-

-

-

Net cash used in investing activities

-19,885

-25,376

-24,939

-11,593

-7,922

-5,454

-5,686

-4,160

-4,414

-1,132

0

0

0

Financing activities
Proceeds from sale of preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from exercise of stock warrants

-

-

-

-

-

-

-

-

-

29

0

0

0

Proceeds from stock options exercised

2,813

2,820

3,363

3,400

2,290

1,871

814

523

256

202

0

0

0

Proceeds from ESPP purchase

991

879

0

0

0

-

-

-

-

-

-

-

-

Proceeds from the issuance of notes payable and warrants, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

0

0

Payments on notes payable

0

-

-

-

-

1,929

0

0

0

-

-

0

0

Net cash provided by financing activities

116,227

116,197

116,694

51,741

1,694

-78

64,434

64,198

73,257

73,249

0

0

0

Net decrease in cash and cash equivalents

62,328

64,634

61,995

12,577

-30,240

-34,253

0

0

0

-

-

-

-

Effect of foreign currency exchange rate on cash

0

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental cash flow information
Accretion of preferred stock to redemption value

-

-

-

-

-

-

-

-

-

4,110

0

0

0

Cash paid for interest

651

656

578

419

585

606

689

715

734

743

0

0

0

Warrants issued to lenders

-

-

-

-

-

-

-

-

-

119

0

0

0

Purchases of property and equipment included in accounts payable

255

164

0

0

0

-

-

-

-

-

0

0

0

Reconciliation of cash, cash equivalents, and restricted cash:
Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

0